NCT07466654

Brief Summary

This study aims to investigate the effects of low-dose caffeine and taurine, administered separately and in combination, on anaerobic, neuromuscular, and cognitive performance. The study is designed as a randomized, double-blind, placebo-controlled crossover trial involving trained man participants. Each participant will complete experimental sessions under different supplementation conditions, including caffeine, taurine, their combination, and placebo. Performance outcomes will include anaerobic power, neuromuscular performance, and cognitive function assessments. The findings will help clarify whether the combined ingestion of caffeine and taurine produces synergistic performance effects compared with isolated supplementation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 15, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 6, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 12, 2026

Completed
Last Updated

March 12, 2026

Status Verified

March 1, 2026

Enrollment Period

1 month

First QC Date

March 6, 2026

Last Update Submit

March 10, 2026

Conditions

Anaerobic Performance Neuromuscular Performance Cognitive Performance

Keywords

caffeinetaurinewingateneuromuscular performancecognitive performance

Outcome Measures

Primary Outcomes (1)

  • Anaerobic Power

    Anaerobic power measured during the Wingate Anaerobic Test following supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo).

    60 minutes after supplementation

Secondary Outcomes (1)

  • Neuromuscular Performance

    60 minutes after supplementation

Study Arms (4)

Caffeine

EXPERIMENTAL

Participants receive caffeine at a dose of 2 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation.

Dietary Supplement: CaffeineDietary Supplement: Placebo

Taurine

EXPERIMENTAL

Participants receive taurine at a dose of 10 mg/kg body mass in capsule form 60 minutes prior to the performance testing session. Anaerobic, neuromuscular, and cognitive performance outcomes are assessed following supplementation.

Dietary Supplement: taurineDietary Supplement: Placebo

Caffeine + Taurine

EXPERIMENTAL

Participants receive a combination of caffeine (2 mg/kg) and taurine (10 mg/kg) in capsule form 60 minutes prior to the performance testing session. Performance assessments include anaerobic, neuromuscular, and cognitive outcomes.

Dietary Supplement: Caffeine + Taurine

Plasebo (Maltodextrine 300 mg)

PLACEBO COMPARATOR

Participants receive a placebo capsule containing maltodextrin (300 mg) 60 minutes prior to the performance testing session. The same performance tests are administered to allow comparison with the supplementation conditions.

Dietary Supplement: Placebo

Interventions

CaffeineDIETARY_SUPPLEMENT

Caffeine administered at a dose of 2 mg/kg body mass in capsule form, 60 minutes prior to performance testing.

Also known as: CAF
Caffeine
taurineDIETARY_SUPPLEMENT

Taurine administered at a dose of 10 mg/kg body mass in capsule form, 60 minutes prior to performance testing.

Also known as: TAU
Taurine
Caffeine + TaurineDIETARY_SUPPLEMENT

Combined supplementation of caffeine (2 mg/kg) and taurine (10 mg/kg) administered 60 minutes prior to testing.

Also known as: CAF+TAU
Caffeine + Taurine
PlaceboDIETARY_SUPPLEMENT

Placebo capsule containing maltodextrin (300 mg) administered 60 minutes prior to testing.

Also known as: PLA
CaffeinePlasebo (Maltodextrine 300 mg)Taurine

Eligibility Criteria

Age18 Years - 25 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsOnly male participants are eligible to participate in this study.
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male participants aged 18 to 25 years
  • Regularly engaged in strength training at least three days per week for the previous 24 months
  • Apparently healthy with no self-reported cardiovascular, metabolic, neurological, or musculoskeletal disorders
  • Free from injuries affecting skeletal muscles, joints, or tendons during the previous two years

You may not qualify if:

  • Use of medications or dietary supplements that may influence physical or cognitive performance
  • Known sensitivity or intolerance to caffeine or taurine
  • Consumption of caffeine or other stimulants within 24 hours prior to the testing sessions
  • Failure to comply with pre-testing instructions or study procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Burdur Mehmet Akif Ersoy University Faculty of Sport Science

Burdur, Merkez, 15100, Turkey (Türkiye)

Location

Related Publications (1)

  • Köse Y, Ulaş M, Atay E. Synergistic Effects of Low-Dose Caffeine and Taurine on Anaerobic, Neuromuscular, and Cognitive Performance: A Double-Blind Randomized Placebo-Controlled Crossover Study. 2026.

    RESULT

Related Links

MeSH Terms

Interventions

CaffeineTaurine

Intervention Hierarchy (Ancestors)

XanthinesAlkaloidsHeterocyclic CompoundsPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingAlkanesulfonic AcidsAlkanesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsSulfonic AcidsSulfur AcidsSulfur Compounds

Study Officials

  • Yakup Köse, MsC

    Burdur Mehmet Akif Ersoy University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: Participants complete multiple experimental sessions under different supplementation conditions (caffeine, taurine, caffeine + taurine, and placebo) in a randomized crossover design. Each participant receives all interventions in separate sessions with appropriate washout periods.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant

Study Record Dates

First Submitted

March 6, 2026

First Posted

March 12, 2026

Study Start

October 15, 2025

Primary Completion

November 15, 2025

Study Completion

November 15, 2025

Last Updated

March 12, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Individual participant-level data will not be publicly shared. Aggregated data supporting the findings of this study may be available from the corresponding author upon reasonable request.

Available IPD Datasets

Informed Consent Form (Informed Consent Form)Access

Locations

TU(1)